- Home
- VYNE vs ALGS Comparison
VYNE vs ALGS Comparison
Compare VYNE & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- ALGS
- Stock Information
- Founded
- VYNE 2003
- ALGS 2018
- Country
- VYNE United States
- ALGS United States
- Employees
- VYNE N/A
- ALGS N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- ALGS Health Care
- Exchange
- VYNE Nasdaq
- ALGS Nasdaq
- Market Cap
- VYNE 35.7M
- ALGS 36.0M
- IPO Year
- VYNE 2018
- ALGS 2020
- Fundamental
- Price
- VYNE $0.94
- ALGS $5.26
- Analyst Decision
- VYNE Strong Buy
- ALGS Strong Buy
- Analyst Count
- VYNE 2
- ALGS 1
- Target Price
- VYNE $6.25
- ALGS $70.00
- AVG Volume (30 Days)
- VYNE 259.3K
- ALGS 163.7K
- Earning Date
- VYNE 05-08-2025
- ALGS 05-06-2025
- Dividend Yield
- VYNE N/A
- ALGS N/A
- EPS Growth
- VYNE N/A
- ALGS N/A
- EPS
- VYNE N/A
- ALGS N/A
- Revenue
- VYNE $605,000.00
- ALGS $3,270,000.00
- Revenue This Year
- VYNE N/A
- ALGS N/A
- Revenue Next Year
- VYNE N/A
- ALGS N/A
- P/E Ratio
- VYNE N/A
- ALGS N/A
- Revenue Growth
- VYNE 43.03
- ALGS N/A
- 52 Week Low
- VYNE $0.95
- ALGS $3.76
- 52 Week High
- VYNE $4.30
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- VYNE 25.37
- ALGS 43.34
- Support Level
- VYNE $0.96
- ALGS $5.12
- Resistance Level
- VYNE $1.09
- ALGS $6.12
- Average True Range (ATR)
- VYNE 0.08
- ALGS 0.54
- MACD
- VYNE -0.01
- ALGS 0.09
- Stochastic Oscillator
- VYNE 3.42
- ALGS 13.53
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.